Ayma Therapeutics

Ayma Therapeutics is a private clinical-stage biotechnology company developing red blood cell–based drug delivery therapies for serious cardiopulmonary and related diseases. Its core approach encapsulates active agents inside red blood cells using the ERYCAPS platform to improve pharmacokinetics, tolerability, and sustained tissue delivery. The company highlights AYX-101 as its lead program, a triciribine phosphate red cell-encapsulated therapy being advanced for pulmonary indications including pulmonary fibrosis, with plans to initiate Phase 1 in 2026. Ayma also describes additional programs spanning cardiovascular disease, ARDS/COVID-19 ARDS, and other future applications enabled by acquired Erytech red-cell encapsulation assets. The company appears focused on translating clinically precedented red-cell encapsulation technology into new therapeutics for high-unmet-need respiratory and cardiovascular conditions.